AstraZeneca vet Jennifer Butler takes charge of Innate Pharma's US biz; C4 raids NIBR
→ France’s Innate Pharma has wooed AstraZeneca vet Jennifer Butler to lead the US operations it has set up after acquiring Lumoxiti from the British drugmaker in a rich add-on collaboration deal. Butler’s official title will be EVP and general manager of Innate Pharma US. Most recently, she was chief business officer, chief commercial officer and head of US operations at Tessa Therapeutics.
→ After celebrating the approval of a Parkinson’s therapy he helped acquired for Acorda Therapeutics, chief business officer Andrew Hindman has decided to step down. Hindman, who joined Acorda in 2014, is now “interested in pursuing opportunities in the wider biopharma industry,” CEO Ron Cohen said. Over the next few transitioning months, he will continue to help evaluate ex-US commercial partnerships for Inbrija as the company awaits a European regulatory decision.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.